Surrozen updates progress on Phase 1b trial for severe alcohol-associated hepatitis and financial results.

From GlobeNewswire: 2024-11-06 09:00:00

Surrozen, Inc. provided financial results and updates on their Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis. Enrollment progress is substantial, with proof-of-concept data expected in the first half of 2025. They also added preclinical ophthalmology product candidates to their R&D pipeline. Additionally, they received a $10 million milestone payment from Boehringer Ingelheim for SZN-413.

SZN-043 is showing promise in its Phase 1b trial for severe alcohol-associated hepatitis, with positive results in cohort 1. No serious adverse events were observed, and patients showed potential clinical benefits. Surrozen expects to present more data at an upcoming liver disease conference. In ophthalmology, they have nominated novel product candidates targeting Fzd4.

Surrozen’s financial results for the third quarter of 2024 showed collaboration and license revenue of $10 million, research and development expenses of $5.2 million, and general and administrative expenses of $3.6 million. They also received a $10 million milestone payment in October 2024. Cash and cash equivalents were $31.0 million as of September 30, 2024.

Surrozen’s strategic partnerships with Boehringer Ingelheim and TCGFB aim to advance their research and development capabilities. They are focused on leveraging their expertise in antibody engineering technologies to target severe liver and eye diseases. Surrozen continues to explore the potential of Wnt signaling in tissue repair and regeneration to transform disease treatment.



Read more at GlobeNewswire:: Surrozen Provides Third Quarter 2024 Financial Results and